ABPI response to Sir Andrew Dillon stepping down as CEO of NICE

Responding to news that Sir. Andrew Dillon is to step down as NICE CEO in March next year, ABPI CEO Mike Thompson said:

"He has played a central role in building the credibility of the organisation, insisting on transparent processes, and a continuous dialogue with all stakeholders, recognising that as the science evolves, NICE needs to evolve too. 

As a result of this leadership, there is a consensus across industry about the central role of NICE in assessing all medicines, ensuring that patients have a right to access the treatments they need.

Hugely respected by all, we thank and congratulate Andrew on his outstanding achievements at NICE, and we wish him all the very best in his future endeavours”.